课题基金 / 基金详情

FUNCTIONS OF VEROTOXIN RECEPTOR GB3 (CD77) IN B CELL FUNCTIONS

FUNCTIONS OF VEROTOXIN RECEPTOR GB3 (CD77) IN B CELL FUNCTIONS
B 细胞功能中维罗毒素受体 GB3 (CD77) 的功能
批准号:
6455789
负责人:
MARK D MALONEY
金额:
$8.4万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2001
资助国家:
美国
项目状态:
已结题
起止时间:
2001-02-01 至 2002-01-31

项目摘要

项目成果

MARK D MALONEY的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Globotriaosyl ceramide (Gb3 or CD77), and potentially other glycosphingolipids which contain Gala-4Gal residues, are receptors for verotoxins (VT's). VT's (also called Shiga-like toxins) produced by E. coli serotype 0157:H7 and other serotypes have been implicated as causative agents in the development of hemorrhagic colitis and the hemolytic uremic syndrome (HUS), which is the leading cause of pediatric acute renal failure. Gb32 is expressed on a variety of human cell types including those of pediatric glomeruli and germinal center B lymphocytes. Previously, we identified VT-like sequences on CD19 and the IFNAR-1 subunit of the interferon-alpha receptor, and we have demonstrated roles for Gb3 in CD19-mediated adhesion and interferon- alpha-induced growth inhibition in Burkitt's lymphoma cells, B cells with a phenotype similar to that of germinal center B cells. Recently we have identified verotoxin-like sequences on human murine MHC class II proteins. Therefore, interactions between Gb3 and MHC class II proteins could play a major role in antigen presentation by lymphocyt4s with a germinal center phenotype. The long term objective of this research is to determine in a comprehensive manner the roles of the VT receptor Gb3 in immune responses and the pathogenic effects on the immune system mediated by VT during human infection with VT-producing E. coli. The specific aims of the proposed research are to identify potential Gb3-binding sites on CD19 and MHC class II proteins using molecular modeling techniques, determine if Gb3 interacts with MHC class II molecules in Burkitt's lymphoma cells, and investigate the mouse as a model for the role of Gb3 in B cell functions.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Globotriaosyl Ceramide (Gb3/CD77) in Burkitt's Lymphoma
  • 批准号:
    6727329
  • 项目类别:
  • 资助金额:
    $25.56万
  • 财政年份:
    2004
  • 负责人:
    MARK D MALONEY
  • 依托单位:
FUNCTIONS OF VEROTOXIN RECEPTOR GB3 (CD77) IN B CELL FUNCTIONS
  • 批准号:
    6592824
  • 项目类别:
  • 资助金额:
    $8.4万
  • 财政年份:
    2002
  • 负责人:
    MARK D MALONEY
  • 依托单位:
FUNCTIONS OF VEROTOXIN RECEPTOR GB3 (CD77) IN B CELL FUNCTIONS
  • 批准号:
    6436441
  • 项目类别:
  • 资助金额:
    $7.41万
  • 财政年份:
    2001
  • 负责人:
    MARK D MALONEY
  • 依托单位:
FUNCTIONS OF VEROTOXIN RECEPTOR GB3 (CD77) IN B CELL FUNCTIONS
  • 批准号:
    6301717
  • 项目类别:
  • 资助金额:
    $7.41万
  • 财政年份:
    2000
  • 负责人:
    MARK D MALONEY
  • 依托单位:
国内基金
海外基金
asr基因调控酸诱导的Escherichia coli O157:H7形成VBNC状态的机制研究
  • 批准号:
    32302245
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    30.00万元
  • 批准年份:
    2023
  • 负责人:
    潘寒姁
  • 依托单位:
小肠中Escherichia coli分泌细菌毒素诱导肠屏障损伤及细菌易位在炎症性肠病中的机制研究
  • 批准号:
    82371775
  • 项目类别:
    面上项目
  • 资助金额:
    46万元
  • 批准年份:
    2023
  • 负责人:
    朱慧媛
  • 依托单位:
基于Escherichia coli O157:H7亚致死态细胞探究超高压与原儿茶酸协同杀菌机制
  • 批准号:
    31871817
  • 项目类别:
    面上项目
  • 资助金额:
    60.0万元
  • 批准年份:
    2018
  • 负责人:
    孙爱东
  • 依托单位:
肠肝轴:从临床患者分离的肠道致病菌株Escherichia coli NF73-1对非酒精性脂肪性肝病的作用及机制研究
  • 批准号:
    81873549
  • 项目类别:
    面上项目
  • 资助金额:
    57.0万元
  • 批准年份:
    2018
  • 负责人:
    刘玉兰
  • 依托单位: